hyperuricemia
Conditions
Interventions
control group:Sodium bicarbonate tablets+Qinling granules simulant
therapeutic group:Sodium bicarbonate tablets+Qinling granules
Sponsors
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Patients with blood uric acid (UA) = 480umol/l and one of the following diseases: hypertension hyperlipidemia diabetes obesity cerebral infarction or coronary heart disease; (2) The syndrome differentiation of traditional Chinese medicine is damp heat type; (3) The age is between 18-70 years old and the gender is not limited; (4) Voluntarily participate in this study and sign the informed consent of enrolled patients.
Exclusion criteria
Exclusion criteria: (1) Taking uric acid lowering drugs in recent 2 weeks; (2) At the same time patients taking diuretics (including but not limited to hydrochlorothiazide furosemide torasemide bumetanide etc.) sglt-2 inhibitors GLP-1 receptor agonists and other drugs that will affect the blood uric acid level; (3) Patients with acute exacerbation of gout; (4) Those whose ALT and AST of liver function exceeded 50% of the upper limit of normal value and those whose SCR of renal function exceeded the upper limit of normal value were not enrolled; (5) Patients with active peptic ulcer; (6) Patients with secondary hyperuricemia (such as kidney disease bone marrow and lymphoproliferative disease diuretic drugs tumor chemotherapy drugs etc.); (7) Those who have serious primary cardiovascular disease liver disease kidney disease hematological disease lung disease or serious diseases that affect their survival such as tumor or AIDS and the investigator believes that they should not be selected; (8) Suspected or true history of alcohol and drug abuse or other diseases that reduce the possibility of enrollment or complicate enrollment according to the judgment of the investigator such as frequent changes in the working environment which are likely to cause loss to follow-up; (9) Patients with asthma angioedema urticaria or allergic reaction after taking diclofenac sodium or other non steroidal anti-inflammatory drugs; (10) Those who are participating in other clinical trials or are participating in other clinical trials; (11) Pregnant or lactating women or those who are allergic to this study drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum uric acid compliance rate(Blood uric acid compliance rate=(number of people with blood uric acid = 360 µ mol/L)/total number of people in the group);Decreased value of blood uric acid;Improvement rate of TCM syndrome score;Decreased values of inflammatory markers (hsCRP, TNF - a, IL6); | — |
Countries
China
Contacts
Public ContactZou Benliang
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Outcome results
None listed